Search Results - "Fleischmann, Roy"

Novel small-molecular therapeutics for rheumatoid arthritis by Fleischmann, Roy

“…PURPOSE OF REVIEWSince the introduction of biologic therapies into the treatment paradigm of rheumatoid arthritis (RA), there has been hope that oral small…”
Get full text

A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis by Fleischmann, Roy M., Bliddal, Henning, Blanco, Francisco J., Schnitzer, Thomas J., Peterfy, Charles, Chen, Su, Wang, Li, Feng, Sheng, Conaghan, Philip G., Berenbaum, Francis, Pelletier, Jean‐Pierre, Martel‐Pelletier, Johanne, Vaeterlein, Ole, Kaeley, Gurjit S., Liu, Wei, Kosloski, Matthew P., Levy, Gwen, Zhang, Lanju, Medema, Jeroen K., Levesque, Marc C.

“…Objective To assess the efficacy and safety of the anti–interleukin‐1α/β (anti–IL‐1α/β) dual variable domain immunoglobulin lutikizumab (ABT‐981) in patients…”
Get full text

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response by Fleischmann, Roy M, Genovese, Mark C, Enejosa, Jeffrey V, Mysler, Eduardo, Bessette, Louis, Peterfy, Charles, Durez, Patrick, Ostor, Andrew, Li, Yihan, Song, In-Ho

“…In SELECT-COMPARE, a randomised double-blind study, upadacitinib 15 mg once daily was superior to placebo or adalimumab on background methotrexate (MTX) for…”
Get more information

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years by van Vollenhoven, Ronald F, Fleischmann, Roy M, Furst, Daniel E, Lacey, Stuart, Lehane, Patricia B

“…Final evaluation of the longterm safety of rituximab (RTX) in rheumatoid arthritis (RA) up to 11 years. Pooled observed case analysis of data from patients…”
Get full text

Looking Back on 2019 in Rheumatology and What to Expect from 2020 by Fleischmann, Roy

Get full text

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement by Nash, Peter, Kerschbaumer, Andreas, Dörner, Thomas, Dougados, Maxime, Fleischmann, Roy M, Geissler, Klaus, McInnes, Iain, Pope, Janet E, van der Heijde, Désirée, Stoffer-Marx, Michaela, Takeuchi, Tsutomu, Trauner, Michael, Winthrop, Kevin L, de Wit, Maarten, Aletaha, Daniel, Baraliakos, Xenofon, Boehncke, Wolf-Henning, Emery, Paul, Isaacs, John D, Kremer, Joel, Lee, Eun Bong, Maksymowych, Walter P, Voshaar, Marieke, Tam, Lai-Shan, Tanaka, Yoshiya, van den Bosch, Filip, Westhovens, René, Xavier, Ricardo, Smolen, Josef S

“…Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to…”
Get more information

Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis? by Pope, Janet E, Fleischmann, Roy M

Get more information

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study by Kavanaugh, Arthur, Fleischmann, Roy M, Emery, Paul, Kupper, Hartmut, Redden, Laura, Guerette, Benoit, Santra, Sourav, Smolen, Josef S

“…To assess the efficacy and safety of adalimumab plus methotrexate (ADA+MTX) compared with methotrexate monotherapy in achieving stable low disease activity…”
Get more information

Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1) by Chandran, Vinod, van der Heijde, Désirée, Fleischmann, Roy M, Lespessailles, Eric, Helliwell, Philip S, Kameda, Hideto, Burgos-Vargas, Ruben, Erickson, Janelle S, Rathmann, Suchitrita S, Sprabery, Aubrey Trevelin, Birt, Julie A, Shuler, Catherine L, Gallo, Gaia

“…Abstract Objective The aim was to assess the safety and efficacy of up to 156 weeks of ixekizumab (an IL-17A antagonist) treatment in PsA patients. Methods In…”
Get full text

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial by Cutolo, Maurizio, Myerson, Gary E, Fleischmann, Roy M, Lioté, Frédéric, Díaz-González, Federico, Van den Bosch, Filip, Marzo-Ortega, Helena, Feist, Eugen, Shah, Kamal, Hu, ChiaChi, Stevens, Randall M, Poder, Airi

“…Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular inflammatory mediator synthesis by elevating cyclic adenosine monophosphate…”
Get full text

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial by Fleischmann, Roy, Prof, Mysler, Eduardo, MD, Hall, Stephen, MD, Kivitz, Alan J, MD, Moots, Robert J, Prof, Luo, Zhen, PhD, DeMasi, Ryan, MD, Soma, Koshika, MD, Zhang, Richard, PhD, Takiya, Liza, PharmD, Tatulych, Svitlana, MD, Mojcik, Christopher, MD, Krishnaswami, Sriram, PhD, Menon, Sujatha, PhD, Smolen, Josef S, Prof

“…Summary Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy…”
Get full text

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis by Fleischmann, Roy, Kremer, Joel, Cush, John, Schulze-Koops, Hendrik, Connell, Carol A, Bradley, John D, Gruben, David, Wallenstein, Gene V, Zwillich, Samuel H, Kanik, Keith S

“…In a placebo-controlled trial, monotherapy with tofacitinib, an oral Janus kinase inhibitor, reduced the symptoms and signs of rheumatoid arthritis. Adverse…”
Get full text

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis by Kloppenburg, Margreet, Peterfy, Charles, Haugen, Ida K, Kroon, Féline, Chen, Su, Wang, Li, Liu, Wei, Levy, Gwen, Fleischmann, Roy M, Berenbaum, Francis, van der Heijde, Désirée, Bansal, Prashant, Wittoek, Ruth, Feng, Sheng, Fang, Yuni, Saltarelli, Mary, Medema, Jeroen K, Levesque, Marc C

“…To assess the efficacy, safety, pharmacokinetics and pharmacodynamics of the anti-interleukin (IL)-1α/β dual variable domain immunoglobulin lutikizumab…”
Get more information

A Summary of 2018 and What Lies Ahead for Rheumatology and Therapy in 2019 by Fleischmann, Roy

Get full text

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study by Feist, Eugen, Fatenejad, Saeed, Grishin, Sergey, Korneva, Elena, Luggen, Michael E, Nasonov, Evgeniy, Samsonov, Mikhail, Smolen, Josef S, Fleischmann, Roy M

“…To assess the efficacy and safety of olokizumab (OKZ), a monoclonal antibody against the interleukin-6 (IL-6) cytokine, versus placebo (PBO) in patients with…”
Get more information

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial by Burmester, Gerd-Rűdiger, Kivitz, Alan J, Kupper, Hartmut, Arulmani, Udayasankar, Florentinus, Stefan, Goss, Sandra L, Rathmann, Suchitrita S, Fleischmann, Roy M

“…CONCERTO was a randomised, double-blind, parallel-armed study of methotrexate (MTX) in combination with adalimumab to assess whether an increasing trend of…”
Get more information

Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis by Smolen, Josef S., Feist, Eugen, Fatenejad, Saeed, Grishin, Sergey A., Korneva, Elena V., Nasonov, Evgeniy L., Samsonov, Mikhail Y., Fleischmann, Roy M.

“…In patients with rheumatoid arthritis, the monoclonal antibody against interleukin-6, olokizumab, was superior to placebo and noninferior to adalimumab at 12…”
Get full text

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment by Feist, Eugen, Fleischmann, Roy M, Fatenejad, Saeed, Bukhanova, Daria, Grishin, Sergey, Kuzkina, Sofia, Luggen, Michael, Nasonov, Evgeniy, Samsonov, Mikhail, Smolen, Josef S

“…To report long-term safety and tolerability of olokizumab (OKZ) in combination with methotrexate (MTX) in subjects with active rheumatoid arthritis (RA), using…”
Get more information

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial by Schiff, Michael, Weinblatt, Michael E, Valente, Robert, van der Heijde, Désirée, Citera, Gustavo, Elegbe, Ayanbola, Maldonado, Michael, Fleischmann, Roy

“…To compare over 2 years the safety, efficacy and radiographic outcomes of subcutaneous abatacept versus adalimumab, in combination with methotrexate (MTX), in…”
Get more information

Tofacitinib versus Methotrexate in Rheumatoid Arthritis by Lee, Eun Bong, Fleischmann, Roy, Hall, Stephen, Wilkinson, Bethanie, Bradley, John D, Gruben, David, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene V, Zang, Chuanbo, Zwillich, Samuel H, van Vollenhoven, Ronald F

“…In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and…”
Get full text